Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Poziotinib in Japanese Patients With NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04402008
Recruitment Status : Recruiting
First Posted : May 26, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:
A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).

Condition or disease Intervention/treatment Phase
NSCLC Drug: Poziotinib Once Daily Dosing Drug: Poziotinib Twice Daily Dosing Drug: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1 Phase 1 Phase 2

Detailed Description:

This is a Phase 1/2, open-label, multicenter study in Japanese patients with locally advanced or metastatic NSCLC. This study will be conducted in two parts. Phase 1 is designed to observe the maximum tolerated dose (MTD) or maximum administered dose (MAD) of poziotinib when administered once daily or twice daily. Phase 2 will evaluate the safety and efficacy of the dose determined in Phase 1. Study participation includes a 30 day screening period, up to 24 months of treatment, and long-term follow-up for a maximum of 24 months after discontinuation of study treatment.

Phase 1 will enroll up to 36 patients into a dose finding study with two parallel, randomized dose groups. Each group will undergo a dose-finding scheme using a 3+3 design with the assessment of dose-limiting toxicities (DLTs) at up to three dose levels. Patients will be randomized into once daily (QD) or twice daily (BID) dose groups. The DLT assessment will be conducted in the first cycle of treatment and therefore, poziotinib dose modifications are not permitted during this cycle. Patients will be hospitalized for the first 2 weeks.

Phase 2 will enroll 40 additional NSCLC patients with EGFR (20 patients) or HER2 (20 patients) exon 20 insertion mutations. Efficacy and safety of the dose and dosing regimen determined in Phase 1 will be evaluated. All patients will be treated in 28-day cycles for up to 24 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Phase 1 will have two randomized, parallel dose groups comparing daily dosing and twice daily dosing at 3 dose levels.

Phase 2 will be a single dose group evaluating the safety and efficacy of the dose determined in Phase 1 in 2 Cohorts. Cohort 1: EGFR exon 20 insertion mutations and Cohort 2: HER2 exon 20 insertion mutations.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : June 26, 2020
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1: Once Daily Dosing
Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
Drug: Poziotinib Once Daily Dosing
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Experimental: Phase 1: Twice Daily Dosing
Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
Drug: Poziotinib Twice Daily Dosing
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.

Experimental: Phase 2: Once Daily Dosing or Twice Daily Dosing

Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.

Cohort 1: EGFR exon 20 insertion mutations

Cohort 2: HER2 exon 20 insertion mutations

Drug: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1
The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.




Primary Outcome Measures :
  1. Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) [ Time Frame: 28 Days ]
    MTD/MAD will be assessed based on the occurrence of defined dose-limiting toxicities (DLT) and all available safety information during first cycle of treatment.

  2. Phase 2: Objective Response Rate (ORR) [ Time Frame: 24 months ]
    The proportion of patients who achieve Complete Response (CR) or Partial response (PR) by the best response from the first dose of poziotinib to the end of the study.


Secondary Outcome Measures :
  1. Phase 2: Disease Control Rate (DCR) [ Time Frame: 24 months ]
    The proportion of patients who achieve CR, PR, and Stable Disease (SD) by the best response from the first dose of poziotinib to the end of the study.

  2. Phase 2: Duration of Response (DoR) [ Time Frame: 24 months ]
    The number of days from the date that measurement criteria are first met for CR or PR (whichever status is recorded first) until the first subsequent date that progressive disease or death is documented.

  3. Phase 2: Progression Free Survival (PFS) [ Time Frame: 24 months ]
    The number of days from the treatment start date to the date of documented disease progression or death.


Other Outcome Measures:
  1. Phase 2: Exploratory - Overall Survival [ Time Frame: 2 years ]
    The number of days from the treatment start date to the date of death due to any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Patient must be willing and capable of giving written Informed Consent, adhering to dosing and visit schedules, and meeting all study requirements
  • Previously treated patient with histologically or cytologically confirmed (archival tissue accepted) locally advanced or metastatic non-small cell lung cancer (NSCLC) and is not a candidate for definitive therapy

    • Phase 1: No test for mutational status is required
    • Phase 2: Documented EGFR or HER2 exon 20 insertion mutations (including duplication mutations) in NSCLC patients
  • Prior treatment status:

    • Phase 1: Patient with refractory NSCLC to available standard therapies
    • Phase 2: Progression after at least one systemic therapy for locally advanced or metastatic disease
  • Patient has measurable NSCLC disease, as per the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Metastatic lesions in bone, CNS, or in brain cannot be used for target lesions.
  • Patient has recovered from prior systemic therapy for metastatic disease to Grade ≤1 for non-hematologic toxicities (except for Grade ≤2 peripheral neuropathy) and has adequate hematologic, hepatic, and renal function at Baseline

Key Exclusion Criteria:

  • Patient is concurrently receiving chemotherapy, biologics, immunotherapy for cancer treatment; systemic anti-cancer treatment or investigational treatment should not be used within 2 weeks prior to Cycle 1, Day 1; local radiation therapy for bone pain may be allowed
  • Patient has used strong inhibitors/inducers of CYP3A4 and CYP2D6 within 1 month prior to Cycle 1, Day 1
  • Patient has had another primary malignancy within 3 years prior to starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ
  • Patient is pregnant or breastfeeding
  • Phase 2 : Patient has had previous treatment with poziotinib. The currently approved TKIs that are not considered to be exon 20 insertion-selective are permissible

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04402008


Contacts
Layout table for location contacts
Contact: Fabio Mataveli 949-788-6700 spi-poz-104@sppirx.com
Contact: Karen Laranjo spi-poz-104@sppirx.com

Locations
Layout table for location information
Japan
National Cancer Center East Recruiting
Kashiwa, Chiba, Japan, 277-8577
Osaka City General Hospital Recruiting
Miyakojima-ku, Osaka, Japan, 534-0021
Shizuoka Cancer Center Recruiting
Sunto-gun, Shizuoka, Japan, 411-8777
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
Investigators
Layout table for investigator information
Study Director: Fabio Mataveli Spectrum Pharmaceuticals, Inc
Layout table for additonal information
Responsible Party: Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier: NCT04402008    
Other Study ID Numbers: SPI-POZ-104
First Posted: May 26, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Spectrum Pharmaceuticals, Inc:
EGFR
HER2
Exon 20 insertion mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases